LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Inclusion Criteria:

- A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving
the trunk and/or limbs

- Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
skin folds) involving 2-30% of the Body Surface Area (BSA)

- An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day
0 (Visit 1)

- A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)

- A target lesion of a minimum of 5 cm at its longest axis and preferably not located
on the extensor surface on an elbow or knee, scoring at least 1 for each of redness,
thickness and scaliness, and at least 4 in total by the Investigator's Assessment of
Severity of the Target Lesion

Exclusion Criteria:

- Systemic treatment with biological therapies, whether marketed or not, with a
possible effect on psoriasis vulgaris within the following time periods prior to
randomisation:

- etanercept - within 4 weeks prior to randomisation

- adalimumab, infliximab - within 8 weeks prior to randomisation

- ustekinumab - within 16 weeks prior to randomisation

- other products - within 4 weeks/5 half-lives prior to randomisation (whichever
is longer)

- Systemic treatment with all other therapies with a possible effect on psoriasis
vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other
immunosuppressants) within 4 weeks prior to randomisation.

- Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug
which has not yet been made available for clinical use following registration) within
4 weeks/5 half-lives (whichever is longer) prior to randomisation.

- PUVA therapy within 4 weeks prior to randomisation.

- UVB therapy within 2 weeks prior to randomisation.

- Topical anti-psoriatic treatment on the trunk and limbs (except for emollients)
within 2 weeks prior to randomisation.

- Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D
analogues or prescription shampoos within 2 weeks prior to randomisation.

- Planned initiation of, or changes to, concomitant medication that could affect
psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors)
during the trial.

- Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

- Previously randomised in this trial or any previously conducted trial of LEO 90100.